Loading clinical trials...

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions | Clinical Trials | Clareo Health

RECRUITINGNA

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in 2 Fractions

NCT07391982•The Netherlands Cancer Institute

Summary

The goal of this clinical trial is to find out whether lowering the radiation dose to parts of the prostate without visible tumor on MRI can reduce side effects while still effectively treating prostate cancer in men with low or intermediate-risk prostate cancer. The main questions it aims to answer are: * Does reducing the radiation dose to healthy prostate tissue lower the risk of bowel and urinary side effects? * Can we maintain good cancer control by keeping a high dose for MRI-visible tumor areas? Researchers will compare two treatment approaches: * One group receives a uniform high dose to the entire prostate. * The other group receives a lower dose to healthy prostate tissue and a high dose only to visible tumor areas. Participants will: * Receive two sessions of MRI-guided radiotherapy using an MR-Linac. * Complete questionnaires about urinary, bowel, and sexual health before and after treatment. * Have follow-up visits to monitor side effects and PSA levels for up to 2 years.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•1. Men aged ≥18 years
•2. Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
•3. Gleason score 3+3, 3+4 or 4+3 (ISUP Grade groups (GG) 1, 2 or 3)
•4. MRI-visible tumour(s) of PIRADS v2 grade 3 or higher and able to be delineated on T2 and diffusion-weighted imaging +/- dynamic contrast-enhanced imaging. Tumour nodule visible on MRI should be considered able to be boosted by treating clinician and \<2.5cm in maximal dimension. MRI must be performed within 3 months of trial entry
•5. The MRI-defined lesion must be confirmed as malignant on biopsies (any Gleason grade is sufficient as long as Gleason score is reported).
•6. MRI stages mT1 and T2 or mT3a with ≤ 1mm tumour outside gland AND otherwise favourable intermediate risk characteristics (Gleason 3+3, 3+4)(as staged by AJCC TNM 2018)
•7. PSA \<20 ng/ml prior to starting androgen deprivation therapy (ADT).
•8. WHO Performance status 0-2
•9. Ability of the participant to understand and the willingness to sign a written informed consent (IC) form.
•10. Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.

Exclusion Criteria

•1. Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)
•2. IPSS Score \> 19
•3. High grade disease (GG3) occult to MRI-defined lesion. As a guide, any pathology for which you would consider surveillance is allowed outside of the MRI-defined area.
•4. Prostate volume \>90cc
•5. Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up
•6. Hip replacement, or other pelvic metalwork which causes artefact on diffusion-weighted imaging
•7. Previous pelvic radiotherapy
•8. Patients needing \>6 months of ADT due to disease parameters.
•9. Previous invasive malignancy within the last 2 years excluding basal or squamous cell carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.

Locations (1)

The Netherlands Cancer Institute

Amsterdam, Netherlands

Key Dates

Start Date

November 17, 2025

Primary Completion Date

February 1, 2027

Completion Date

December 1, 2028

Last Updated

February 6, 2026

Enrollment

ESTIMATED participants

Conditions

Prostate Cancer (Adenocarcinoma)

Interventions

uniform dose radiotherapy

RADIATION

De-escalated dose radiotherapy

RADIATION

Contacts

Floris Pos, MD, PhD

CONTACT

+31205129111 f.pos@nki.nl

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597

Prostate Cancer (Adenocarcinoma)Metastatic Prostate Cancer

View study

RECRUITINGNA

PSMA PET for Surveillance After Focal Therapy

NCT07115914

Prostate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

Inclusion Criteria

Exclusion Criteria

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

PSMA PET for Surveillance After Focal Therapy

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma